Study reveals a decline in the use of erythropoiesis-stimulating agents and an increase in the use of iron.
Each 0.5 mg/dL increment in phosphorus was associated with a 7% increased risk of anemia.
Ordering process cut the number of epoetin alfa doses by 71% and medication costs by 69%.
In a head-to-head comparison, researchers observed a higher rate of adverse events with iron dextran than iron sucrose or ferric gluconate.
Iron absorbed from oral ferric citrate boosted iron stores and sustained hemoglobin levels.
Patients with higher levels of anti-CMV antibodies have lower number of red blood cells.
CORAL study chair Lance Dworkin, MD, discusses the controversial finding with Renal & Urology News.
Greater resistance to ESA is associated with an increased risk of death among patients on chronic HD.
Considerable variation in incidence of HAA across hospitals; teaching status and region linked to risk.
Serum hepatitis E virus levels were undetectable in 78% of patients at least 6 months after stopping treatment.
Ferumoxytol and iron sucrose have comparable safety in the treatment of anemia in patients with CKD.
Platelets may aggregate more easily in iron-deficient patients.
Soluble ferric pyrophosphate (Triferic), an investigational drug, is delivered to hemodialysis patients via dialysate.
Geriatric patients with CKD are at high risk for morbidity and mortality from the potential side effects of treatments.
In a study, ferumoxytol and iron sucrose treatment was associated with comparable increases in hemoglobin levels and adverse event rates.
This trait in African-American hemodialysis patients was associated with a 13.2% higher dose of erythropoiesis-stimulating agents.
Decreasing TSAT and higher ESA doses are associated with increasing platelet counts.
Folic acid treatment significantly improved hemoglobin levels and decreased epoetin alfa use.
Elemental iron requirement was reduced by half in patients receiving ferric citrate versus an active control.
These include use of lower ESA doses and hemoglobin levels.
Weekly dose of erythropoiesis-stimulating agents decreased and hemoglobin levels increased.
Patients with levels below 10 g/dL had the highest unadjusted mortality and all-cause hospitalization rates.
A transferrin saturation of 20% or less was associated with a 2.2 times increased risk of death from any cause.
Study also documents use of higher IV iron doses and declining hemoglobin levels.
Plasma ascorbic acid levels in the physiologic range correlated inversely with EPO resistance.
Soluble ferric pyrophosphate is a unique carbohydrate-free formulation administrated via dialysate.
Children on dialysis who have anemia and require high doses of drugs to treat it are at increased risk of dying prematurely.
Soluble ferric pyrophosphate significantly decreased ESA use while maintaining target hemoglobin levels without increasing iron stores.
The trend is most pronounced among Medicare recipients since the debut of bundling, ESA labeling changes.
Study also showed an increase in the proportion of patients with hemoglobin level below 10 g/dL and in transfusion rates.